Biomedical Engineering Reference
In-Depth Information
Table 1.2
(
Continued
)
Biomarker
Application
Drug*
Chapter
Onco
type
DX assay
Adjuvant chemotherapy plus endocrine therapy for high
risk while adjuvant endocrine therapy for low risk early ER-
positive and node-negative breast cancer
CMF or tamoxifen
13
α
PML/RAR(
) gene expression Treatment with ATRA may be based on its expression for
acute promyelocytic leukemia
ATRA; arsenic
oxide
10
TPMT deficiency or low
activity
At increased risk of myelotoxicity. TPMT testing is
recommended and consideration can be given to genotype or
phenotype patients for TPMT
Mercaptopurine,
azathioprine
_
UGT1A1 polymorphisms and
mutation
A reduced initial dose for homozygous UGT1A1*28 allele
Irinotecan
12
*Prototype drug.
ATRA, all trans retinoic acid; Ph+, philadelphia-positive chromosome; DPD, dihydropyrimine dehydrogenase; EGFR, epidermal growth factor receptor;
ER, estrogen receptor; PR, progesterone receptor; echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase; HER2, human
epidermal growth receptor 2; GIST, gastrointestinal stromal tumors; ALL, acute lymphocytic leukemia; NSCLC, Non-Small Cell Lung Cancer; Topo II,
topoisomerase II alpha; TPMT, thiopurine S-methyltransferase.
